跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,382 条关于
“Cohen-Mansfield Agitation Inventory”
全部
1,382
临床试验
759
药物
11
机构
16
资讯
596
去年
Kinoxis Therapeutics Receives $2.5M Grant to Advance KNX100 for Dementia Agitation
去年
ECT Shows Promise in Managing Behavioral Symptoms of Dementia
去年
Axsome Submits FDA Application for AXS-05 in Alzheimer's Disease Agitation Following Positive Phase 3 Results
去年
IGC Pharma Reports Promising Interim Results for Alzheimer's Agitation Therapy
去年
Axsome's AXS-05 Shows Promise in Alzheimer's Agitation Trials, NDA Submission Planned for 2025
8个月前
Neumora's NMRA-511 Shows Clinically Meaningful Results in Phase 1b Alzheimer's Agitation Study
4个月前
FDA Approves Auvelity for Alzheimer's Disease Agitation, Marking Second Approved Treatment Option
去年
Synthetic THC Shows Promise in Reducing Agitation in Alzheimer's Patients
去年
Compugen Announces Key Leadership Transition: CEO Cohen-Dayag to Become Executive Chair as CSO Ophir Takes Helm
去年
FDA Approves Rexulti as Breakthrough Treatment for Alzheimer's-Related Agitation
第 1 页，共 60 页
上一页
下一页
